Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amazon.com Inc (AMZN) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance

Amazon.com IncTrade
Citius Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Amazon.com Inc vs Citius Pharmaceuticals Inc — how do they compare? Amazon.com Inc trades at $267.53 (market cap $2.94T), while Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M). The key difference: Amazon.com Inc is far larger — about 146926.5× Citius Pharmaceuticals Inc's market cap, and Amazon.com Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

AMZNCTXR
Market Cap
$2.94T$20.01M
Volume
3,931,282
Sector
Consumer CyclicalHealth
52-Week High
$284.02$1.82
52-Week Low
$198.79$0.48
Enterprise Value
$3.04T$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amazon.com Inc

Amazon (AMZN) trades at $268.92, down 3.3% over the past 24 hours, but maintains strong fundamental momentum with revenue growing to $716.92 billion in 2025 and net income reaching $77.67 billion. The stock shows a bullish technical setup with moving averages supporting upward momentum, while analyst sentiment remains overwhelmingly positive with 89% buy ratings and a $333.86 consensus price target representing 24% upside potential.

Amazon's outlook remains favorable with accelerating AI-driven growth in AWS and expanding profit margins, though investors face risks from intense retail competition and substantial capital expenditures. The company's dominant market position and strong cash flow generation support continued expansion, but execution on massive infrastructure investments will be critical for sustained shareholder returns.

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amazon.com Inc

Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.

Read more on AMZN

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR